Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2009
Event: Entry into a Material Definitive Agreement with Xcellerex, Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a specific contractual agreement regarding manufacturing services.
Material Changes and Agreement Terms
On October 20, 2009, Novavax entered into a binding term sheet with Xcellerex, Inc. to manufacture bulk drug substance for Novavax's 2009 H1N1 vaccine intended for potential use and sale in Mexico.
- Payment Structure: Novavax will pay fixed non-refundable prepayments and a per-dose fee for accepted doses. Novavax receives credits for materials supplied to Xcellerex and a portion of the prepayment per batch.
- Security: Novavax must provide a letter of credit equal to the estimated aggregate per-dose fee for one batch, which rolls over until payment in full or termination.
- Exclusivity: Xcellerex is the exclusive contract manufacturer for the Mexican market until February 15, 2010, and a co-exclusive provider for other markets through June 2010.
Guidance, Risks, and Termination Provisions
The agreement includes specific termination rights and contingencies:
- Termination by Novavax: Novavax may terminate on or before December 2, 2009. In this case, Xcellerex retains prepayments made plus the value of used materials, must return unused materials, and deliver completed bulk material.
- Conditional Termination: Novavax may terminate prior to January 15, 2010, if clinical trials are delayed due to safety or immunogenicity issues, if regulatory approval is not sought, or if approval is rejected. Xcellerex retains prepayments in this scenario.
- Post-Termination Sales: If the agreement is terminated between December 2, 2009, and January 15, 2010, and Novavax sells produced bulk material to a third party, Novavax must pay the per-dose fee.
Investor Verification Checklist
- Verify the total amount of the non-refundable prepayment and the specific per-dose fee rates.
- Confirm the status of the clinical trials and regulatory approval applications in Mexico.
- Assess the impact of the letter of credit requirement on Novavax's available liquidity.
- Review the press release dated October 21, 2009 (Exhibit 99.1) for additional commercial context.